Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
January 10, 2007New England Journal of MedicineOpen Access

Sorafenib in Advanced Clear-Cell Renal-Cell Carcinoma

View Full Paper
Ask AI
Bookmark
Share

Authors

Bernard EscudierBernard EscudierUniversité Claude Bernard Lyon 1TETim EisenUniversity of CambridgeWSWalter M. StadlerRutgers, The State University of New Jersey

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Escudier et al. (2007) studied this question.

synapsesocial.com/papers/69d9631a8988aeabbe68518dhttps://doi.org/10.1056/nejmoa060655
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1A Randomized Trial of Bevacizumab, an Anti–Vascular Endothelial Growth Factor Antibody, for Metastatic Renal Cancer2003 · 2,705 citations
  2. 2End Points and United States Food and Drug Administration Approval of Oncology Drugs2003 · 483 citations
  3. 3Do cytokines improve survival in patients with metastatic renal cell carcinoma (MRCC) of intermediate prognosis? Results of the prospective randomized PERCY Quattro trial2005 · 89 citations
  4. 4Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy.1995 · 1,403 citations